Experimental validation and pan-cancer analysis identified COL10A1 as a novel oncogene and potential therapeutic target in prostate cancer
Figure 3.Kaplan–Meier survival analyses of the prognostic value of COL10A1 expression level for DSS in different cancer types. DSS according to high and low expression of COL10A1 in KIRC, KIRP, PAAD and UCEC from the TCGA database (A–D).